


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
HSMN NewsFeed - 15 Apr 2021
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive
HSMN NewsFeed - 14 Apr 2021
HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer
HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer
HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
HSMN NewsFeed - 13 Apr 2021
Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer
Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer
HSMN NewsFeed - 6 Apr 2021
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
HSMN NewsFeed - 5 Apr 2021
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
HSMN NewsFeed - 30 Mar 2021
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 19 Mar 2021
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
HSMN NewsFeed - 17 Mar 2021
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 9 Mar 2021
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
HSMN NewsFeed - 1 Mar 2021
Perrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
Perrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
